These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20220430)

  • 1. Intravitreal bevacizumab with regression of subretinal neovascularization after intraocular foreign body trauma.
    Chen TL; Sun MH; Lin KK; Lai CC; Chen KJ
    J Trauma; 2010 Mar; 68(3):747. PubMed ID: 20220430
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A.
    Mavrakanas N; Mendrinos E; Pournaras CJ; Salzmann J
    Acta Ophthalmol; 2009 Nov; 87(8):930-2. PubMed ID: 19706015
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab: a word of caution.
    Kumar N; Sebastian R; Harding S; Pearce I
    Can J Ophthalmol; 2007 Oct; 42(5):760-1. PubMed ID: 17891210
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization.
    Arriola-Villalobos P; Donate-López J; Calvo-González C; Reche-Frutos J; Alejandre-Alba N; Díaz-Valle D
    Acta Ophthalmol; 2008 Feb; 86(1):115-6. PubMed ID: 17680838
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
    Spandau UH; Jonas JB
    Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
    Kumar A; Sinha S
    Can J Ophthalmol; 2007 Apr; 42(2):335-6. PubMed ID: 17392871
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravitreal bevacizumab for retinal macroaneurysm.
    Jonas JB; Schmidbauer M
    Acta Ophthalmol; 2010 Nov; 88(7):e284. PubMed ID: 20977692
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of intravitreal bevacizumab in experimental posterior penetrating eye injury.
    Mehdizadeh M; Fattahi F; Eghtedari M; Nowroozzadeh MH; Toosi F
    Retina; 2011 Jan; 31(1):154-60. PubMed ID: 20838359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
    Siqueira RC; Costa RA; Scott IU; Cintra LP; Jorge R
    Acta Ophthalmol Scand; 2006 Dec; 84(6):834-5. PubMed ID: 17083555
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin).
    Thew M
    Clin Exp Optom; 2009 Jan; 92(1):34-7. PubMed ID: 19125745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation.
    Wolf A; Thurau S; Kook D; Hoeing A; Priglinger S; Kampik A; Haritoglou C
    Acta Ophthalmol; 2010 Nov; 88(7):e295-6. PubMed ID: 19860782
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration.
    Mete A; Saygili O; Mete A; Bayram M; Bekir N
    J Clin Ultrasound; 2010 Feb; 38(2):66-70. PubMed ID: 19953626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy.
    Kernt M; Gschwendtner A; Neubauer AS; Dichgans M; Haritoglou C
    J Neurol; 2010 Jul; 257(7):1213-4. PubMed ID: 20179959
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.
    Miki K; Miki A; Matsuoka M; Muramatsu D; Hackett SF; Campochiaro PA
    Ophthalmology; 2009 Sep; 116(9):1748-54. PubMed ID: 19643496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
    Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2006 Oct; 84(5):707-8. PubMed ID: 16965507
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal bevacizumab for idiopathic choroidal neovascularization.
    Cakir M; Cekiç O; Yilmaz OF
    J AAPOS; 2009 Jun; 13(3):296-8. PubMed ID: 19285890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
    Fong KC; Barry C; McAllister IL
    Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.